Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses

@article{Swenson2008MonovalentVP,
  title={Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses},
  author={Dana L. Swenson and Kelly L. Warfield and Tom Larsen and Derron A. Alves and Sadie S. Coberley and Sina Bavari},
  journal={Expert Review of Vaccines},
  year={2008},
  volume={7},
  pages={417 - 429}
}
Background: Virus-like particle (VLP)-based vaccines have the advantage of being morphologically and antigenically similar to the live virus from which they are derived. Expression of the glycoprotein and VP40 matrix protein from Lake Victoria marburgvirus (MARV) results in spontaneous production of VLPs in mammalian cells. Guinea pigs vaccinated with Marburg virus VLPs (mVLPs) or inactivated MARV (iMARV) develop homologous humoral and T-cell responses and are completely protected from a lethal… 
Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges)
TLDR
MARV VLPs induce IgG antibodies recognizing MARV GP and VP40 and protect cynomolgus macaques from an otherwise lethal aerosol exposure with MARV.
Homologous and Heterologous Protection of Nonhuman Primates by Ebola and Sudan Virus-Like Particles
TLDR
Using the EBOV nonhuman primate model, it is shown that one or two doses of VLP vaccine can confer protection from lethal infection and this observation provides strong evidence that it will be possible to develop and administer a broad-spectrum VLP-based vaccine that will protect against multiple filoviruses by combining only three E BOV, SUDV and MARV components.
Marburg virus-like particles by co-expression of glycoprotein and matrix protein in insect cells induces immune responses in mice
TLDR
Marburg virus-like particles (VLPs) generated by co-expressing the glycoprotein (GP) and matrix protein (VP40) using the baculovirus expression system may constitute an effective vaccination and PCP-II should be further investigated as a novel adjuvant.
Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein.
TLDR
The potential for eliciting effective immune responses against EBOV, Sudan virus, and MARV with a single GP construct was tested, and it is shown that higher antibody responses were elicited by the C terminal region of GP1 than by the N terminal region, and this correlated with protection.
Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates
TLDR
RVSV filovirus GP vaccine vectors lack the neurovirulence properties associated with the rVSV-wt parent vector and support their further development as a vaccine platform for human use.
Ad35 and Ad26 Vaccine Vectors Induce Potent and Cross-Reactive Antibody and T-Cell Responses to Multiple Filovirus Species
TLDR
Combination of the five selected filov virus glycoproteins in one multivalent vaccine potentially elicits protective immunity in man against all major filovirus strains that have caused lethal outbreaks in the last 20 years.
Advances in virus-like particle vaccines for filoviruses.
TLDR
The ability of the VLP vaccines containing GP, NP, and VP40 to confer complete homologous protection against Ebola virus and Marburg virus in a prophylactic setting against in macaques is shown.
Vesicular Stomatitis Virus-Based Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus
TLDR
Heterologous rVSV-based filovirus vaccine vectors employed in the prime-boost approach can provide protection against BEBOV using an abbreviated regimen, which may have utility in outbreak settings.
Rapid and Durable Protection Against Marburg Virus with a Single-Shot ChAd3-MARV GP Vaccine
TLDR
It is demonstrated that a single-shot ChAd3 MARV vaccine generated a protective immune response that was both rapid and durable with a significant immune correlate of protection that will support advanced clinical development.
...
...

References

SHOWING 1-10 OF 45 REFERENCES
Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates.
TLDR
An RNA replicon, based upon Venezuelan equine encephalitis (VEE) virus, was used as a vaccine vector; the VEE structural genes were replaced by genes for MBGV GP, nucleoprotein (NP), VP40, VP35, VP30, or VP24.
Cross-Protection against Marburg Virus Strains by Using a Live, Attenuated Recombinant Vaccine
TLDR
Protection against two heterologous MARV strains, the seemingly more pathogenic Angola strain and the more distantly related Ravn strain is evaluated, suggesting that the VSVΔG/MARVGP-Musoke vaccine should be sufficient to protect against all knownMARV strains.
Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents.
TLDR
It is suggested that filovirus-like particles produced by baculovirus expression systems, which are amenable to large-scale production, are highly immunogenic and are suitable as safe and effective vaccines for the prevention of filoviral infection.
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses
TLDR
The data suggest that these replication-competent vaccines against EBOV and MARV based on attenuated recombinant vesicular stomatitis virus vectors are safe and highly efficacious in a relevant animal model.
Filovirus-like particles as vaccines and discovery tools
TLDR
In addition to their use as a vaccine, VLPs are currently being used as tools to learn lessons about filovirus pathogenesis, immunology, replication and assembly requirements.
Vaccine To Confer to Nonhuman Primates Complete Protection against Multistrain Ebola and Marburg Virus Infections
TLDR
Vaccination of nonhuman primates demonstrated 100% protection against infection by two species of Ebola virus and three Marburg virus subtypes, each administered at 1,000 times the lethal dose.
...
...